<div id="readability-page-1"><p>North Star Asset Management Inc. boosted its position in  Abbott Laboratories (NYSE:ABT - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor  owned 316,783 shares of the healthcare product maker's stock after acquiring an additional 12,271 shares during the quarter. Abbott Laboratories accounts for about  1.6% of North Star Asset Management Inc.'s holdings, making the stock its 11th biggest holding. North Star Asset Management Inc.'s holdings in Abbott Laboratories were worth $39,690,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li></ul><p>Other hedge funds have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. acquired a new stake in  Abbott Laboratories in the fourth quarter valued at approximately $27,000.  Cloud Capital Management LLC acquired a new stake in  Abbott Laboratories during the third quarter worth approximately $29,000.  Guerra Advisors Inc acquired a new stake in  Abbott Laboratories during the third quarter worth approximately $31,000.  Bridge Generations Wealth Management LLC acquired a new stake in  Abbott Laboratories during the third quarter worth approximately $33,000.  Finally, Copia Wealth Management acquired a new stake in  Abbott Laboratories during the third quarter worth approximately $38,000. Institutional investors and hedge funds own  75.18% of the company's stock. </p><h2>Abbott Laboratories Stock Performance</h2><p>Shares of Abbott Laboratories stock opened at $87.42 on Friday. The firm's fifty day simple moving average is $96.74 and its 200-day simple moving average is $112.05. The stock has a market capitalization of $152.27 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. </p><ul><li>Abbott Stock Crash: Rebound Could Be Coming Fast</li></ul><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company's quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS.  As a group, equities analysts forecast that  Abbott Laboratories will post 5.48 earnings per share for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of analysts have weighed in on the stock. Daiwa Securities Group cut shares of Abbott Laboratories from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. Wells Fargo &amp; Company cut their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Citigroup cut their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, April 17th. Argus cut their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, April 21st. Finally, Piper Sandler cut their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned  a Buy rating and five have assigned  a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $119.43.</p><ul><li>A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?</li></ul><p><b>Check Out Our Latest Stock Report on ABT</b></p><h2>More Abbott Laboratories News</h2><p>Here are the key news stories impacting Abbott Laboratories this week:</p><ul>   <li><span>Positive Sentiment: </span>A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. <i></i><span>3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26</span></li>   <li><span>Positive Sentiment: </span>Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&amp;D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. <i></i><span>Abbott’s Lingo Wearable And Cardio R&amp;D Reframe Long Term Growth Story</span></li>   <li><span>Neutral Sentiment: </span>One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. <i></i><span>Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)</span></li>   <li><span>Negative Sentiment: </span>Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. <i></i><span>Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum</span></li>   <li><span>Negative Sentiment: </span>Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. <i></i><span>Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure</span></li> </ul><h2>Insiders Place Their Bets</h2><p>In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the company's stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own  0.46% of the company's stock. </p><h2>Abbott Laboratories Profile</h2> (Free Report)<p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.  </p><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p><h2>Read More</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>Workday Validates AI Flywheel: Stock Price Recovery Begins</li><li>HubSpot at 2019 Levels Is an Opportunity—Not a Warning</li><li>Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?</li><li>Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally</li></ul><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>North Star Asset Management Inc. increased its stake in Abbott Laboratories (NYSE:ABT) by 4.0% in Q4, owning 316,783 shares valued at $39.69 million. The company is now the 11th largest holding for North Star. Other hedge funds also acquired stakes in Abbott. The stock opened at $87.42, with a market cap of $152.27 billion. Analysts have mixed ratings, with a consensus rating of 'Moderate Buy' and a price target of $119.43.</p>

Market Beat

Abbott Laboratories

SPDR S&P Health Equip

Ark Genomic Revolution ETF

iShares Global Healthcare

VG Health

Health Care Select Sector SPDR

iShares US Pharma

iShares US Medical Devices

Abbvie

Daiwa Securities Group Inc.

Wells Fargo

Citigroup

Piper Sandler Cos

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Abbott Laboratories $ABT Shares Purchased by North Star Asset Management Inc.